333 related articles for article (PubMed ID: 26859637)
1. Tenofovir and bone health.
Grant PM; Cotter AG
Curr Opin HIV AIDS; 2016 May; 11(3):326-32. PubMed ID: 26859637
[TBL] [Abstract][Full Text] [Related]
2. A 10-year follow-up of bone mineral density in HIV-infected youths receiving tenofovir disoproxil fumarate.
Giacomet V; Maruca K; Ambrosi A; Zuccotti GV; Mora S
Int J Antimicrob Agents; 2017 Sep; 50(3):365-370. PubMed ID: 28689877
[TBL] [Abstract][Full Text] [Related]
3. The Epi-TAF for Tenofovir Disoproxil Fumarate?
Walensky RP; Horn TH; Paltiel AD
Clin Infect Dis; 2016 Apr; 62(7):915-8. PubMed ID: 26658300
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.
Kim-Chang JJ; Wilson L; Chan C; Fischer B; Venturi G; Goodenow MM; Aldrovandi G; Weber TJ; Sleasman JW;
AIDS Res Hum Retroviruses; 2019 Aug; 35(8):746-754. PubMed ID: 31115244
[TBL] [Abstract][Full Text] [Related]
5. Osteoporosis-Related Fractures in HIV-Infected Patients Receiving Long-Term Tenofovir Disoproxil Fumarate: An Observational Cohort Study.
Komatsu A; Ikeda A; Kikuchi A; Minami C; Tan M; Matsushita S
Drug Saf; 2018 Sep; 41(9):843-848. PubMed ID: 29623648
[TBL] [Abstract][Full Text] [Related]
6. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
Mugwanya KK; Baeten JM
Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852
[TBL] [Abstract][Full Text] [Related]
7. The protease inhibitors and HIV-associated bone loss.
Moran CA; Weitzmann MN; Ofotokun I
Curr Opin HIV AIDS; 2016 May; 11(3):333-42. PubMed ID: 26918650
[TBL] [Abstract][Full Text] [Related]
8. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
[TBL] [Abstract][Full Text] [Related]
10. What's new in bone disease and fractures in HIV?
Alvarez-Barco E; Mallon PWG
Curr Opin HIV AIDS; 2021 May; 16(3):186-191. PubMed ID: 33843807
[TBL] [Abstract][Full Text] [Related]
11. Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review.
Okonkwo RI; Weidmann AE; Effa EE
Drug Saf; 2016 Mar; 39(3):209-18. PubMed ID: 26692394
[TBL] [Abstract][Full Text] [Related]
12. Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments.
Achhra AC; Nugent M; Mocroft A; Ryom L; Wyatt CM
Curr HIV/AIDS Rep; 2016 Jun; 13(3):149-57. PubMed ID: 27130284
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients.
Cheng CY; Chang SY; Lin MH; Ku SY; Sun NL; Cheng SH
J Infect Chemother; 2016 Nov; 22(11):744-747. PubMed ID: 27613487
[TBL] [Abstract][Full Text] [Related]
14. Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults.
Agbaji OO; Abah IO; Ebonyi AO; Gimba ZM; Abene EE; Gomerep SS; Falang KD; Anejo-Okopi J; Agaba PA; Ugoagwu PO; Agaba EI; Imade GE; Sagay AS; Okonkwo P; Idoko JA; Kanki PJ
J Int Assoc Provid AIDS Care; 2019; 18():2325958218821963. PubMed ID: 30672363
[TBL] [Abstract][Full Text] [Related]
15. Maternal Tenofovir Disoproxil Fumarate Use During Pregnancy Is Not Associated With Adverse Perinatal Outcomes Among HIV-infected East African Women: A Prospective Study.
Pintye J; Baeten JM; Celum C; Mugo N; Ngure K; Were E; Bukusi EA; John-Stewart G; Heffron RA
J Infect Dis; 2017 Dec; 216(12):1561-1568. PubMed ID: 29040666
[TBL] [Abstract][Full Text] [Related]
16. Chest Deformity and Disability due to Tenofovir-Induced Hypophosphatemic Osteomalacia: Case Report and Call for Improved Global Access to Laboratory Testing.
Hajek J; Ouma S; Hemmett J; Starko R; Apiyo P
J Int Assoc Provid AIDS Care; 2017; 16(5):430-432. PubMed ID: 28689456
[TBL] [Abstract][Full Text] [Related]
17. Acute Kidney Injury, Risk Factors, and Prognosis in Hospitalized HIV-Infected Adults in South Africa, Compared by Tenofovir Exposure.
Seedat F; Martinson N; Motlhaoleng K; Abraham P; Mancama D; Naicker S; Variava E
AIDS Res Hum Retroviruses; 2017 Jan; 33(1):33-40. PubMed ID: 27478997
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir exposure alters associations of serum bicarbonate with chronic kidney disease risk in HIV-infected veterans.
Kim JE; Scherzer R; Estrella MM; Ix JH; Shlipak MG
AIDS; 2016 Apr; 30(7):1049-57. PubMed ID: 26760455
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with fractures in HIV-infected persons: which factors matter?
Gedmintas L; Wright EA; Dong Y; Lehmann E; Katz JN; Solomon DH; Losina E
Osteoporos Int; 2017 Jan; 28(1):239-244. PubMed ID: 27421978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
